Sales ended at MNOK 61.6 for the quarter (MNOK 52.0), an 18.5 % growth. Sales as of September increased by 18.9 % and ended at MOK 176.8 (MNOK 148.7). Operating profit (EBIT) for the quarter ended at MNOK 12.7 (MNOK 10.0). Operating profit as of September ended at MNOK 34.3 (MNOK 28.9) after an accrual of MNOK 3.2 related to termination of the Medtronic
Profit per share increased with 32 % for the quarter and ended at NOK 0.57 (NOK 0.43). As of September profit per share was NOK1.56 (NOK 1.12).
The positive development in USA continues with a currency neutral growth of 6.7 % for the quarter. Currency neutral growth as of September was 10.7 %. Medistim introduced its new product within vascular surgery in the 3rd quarter.